Form 8-K - Current report:
SEC Accession No. 0001628280-22-008804
Filing Date
2022-04-08
Accepted
2022-04-08 15:34:34
Documents
17
Period of Report
2022-04-08
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20220408.htm   iXBRL 8-K 40046
2 EX-99.1 a991ex040822.htm EX-99.1 23835
3 EX-99.2 a992ex040822.htm EX-99.2 16937
7 crdf-20220408_g1.jpg GRAPHIC 176318
8 image_0.jpg GRAPHIC 17916
9 image_01.jpg GRAPHIC 17916
  Complete submission text file 0001628280-22-008804.txt   712297

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20220408.xsd EX-101.SCH 1929
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20220408_lab.xml EX-101.LAB 22963
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20220408_pre.xml EX-101.PRE 12087
11 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20220408_htm.xml XML 10065
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 22816803
SIC: 2836 Biological Products, (No Diagnostic Substances)